Redmile Group LLC increased its holdings in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 1.6% in the first quarter, HoldingsChannel.com reports. The fund owned 4,485,417 shares of the biotechnology company’s stock after purchasing an additional 70,800 shares during the quarter. Atara Biotherapeutics accounts for approximately 5.2% of Redmile Group LLC’s portfolio, making the stock its 4th largest position. Redmile Group LLC owned 0.10% of Atara Biotherapeutics worth $178,295,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ATRA. JPMorgan Chase & Co. lifted its stake in Atara Biotherapeutics by 53.8% in the first quarter. JPMorgan Chase & Co. now owns 1,917,903 shares of the biotechnology company’s stock worth $76,237,000 after acquiring an additional 671,216 shares during the period. Norges Bank purchased a new stake in Atara Biotherapeutics in the fourth quarter worth about $20,648,000. Federated Investors Inc. PA lifted its stake in Atara Biotherapeutics by 47.6% in the first quarter. Federated Investors Inc. PA now owns 903,307 shares of the biotechnology company’s stock worth $35,906,000 after acquiring an additional 291,207 shares during the period. Dimensional Fund Advisors LP lifted its stake in Atara Biotherapeutics by 107.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 474,973 shares of the biotechnology company’s stock worth $16,500,000 after acquiring an additional 245,832 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in Atara Biotherapeutics in the fourth quarter worth about $6,673,000.

A number of brokerages have commented on ATRA. Stifel Nicolaus began coverage on shares of Atara Biotherapeutics in a report on Wednesday, May 22nd. They issued a “buy” rating and a $41.00 target price for the company. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 4th. Citigroup upgraded shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $23.00 to $24.00 in a report on Monday, June 3rd. ValuEngine upgraded shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, April 1st. Finally, Mizuho reiterated a “buy” rating and issued a $62.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. Atara Biotherapeutics presently has a consensus rating of “Buy” and a consensus price target of $40.40.

In other news, insider Joe Newell sold 1,500 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $39.96, for a total transaction of $59,940.00. Following the transaction, the insider now owns 63,646 shares in the company, valued at $2,543,294.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 3,900 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $37.04, for a total value of $144,456.00. Following the completion of the sale, the chief executive officer now owns 332,243 shares in the company, valued at approximately $12,306,280.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,150 shares of company stock worth $1,147,091. Corporate insiders own 10.60% of the company’s stock.

ATRA opened at $21.85 on Monday. Atara Biotherapeutics Inc has a 52-week low of $21.31 and a 52-week high of $47.22. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.96 and a current ratio of 9.96. The stock has a market cap of $1.01 billion, a PE ratio of -4.15 and a beta of 2.36.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.48) by $0.04. On average, analysts anticipate that Atara Biotherapeutics Inc will post -5.54 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/redmile-group-llc-has-178-30-million-position-in-atara-biotherapeutics-inc-nasdaqatra/3044110.html.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

See Also: Market Perform

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.